Digestive Diseases and Sciences

, Volume 54, Issue 9, pp 1966–1970 | Cite as

Helicobacter pylori Infection as a Risk Factor for Insulin Resistance

  • Ahad Eshraghian
  • Seyed Ali Hashemi
  • Alireza Hamidian Jahromi
  • Hamed Eshraghian
  • Seyed Masoum Masoompour
  • Mohamad Ali Davarpanah
  • Kavus Eshraghian
  • Seyed Alireza Taghavi
Original Article


This study aimed to determine the relation between Helicobacter pylori infection and insulin resistance in healthy subjects. In a cross-sectional case control study between January and April 2007, a total of 71 healthy subjects without the exclusion criteria completed the study. Forty-three (60.6%) patients were H. pylori positive and 28 (39.4%) patients were H. pylori negative. Age and body mass index of the patients were not significantly different between the two groups (32.2 ± 14.2 vs. 33 ± 8.05 years and 23.15 ± 4.5 vs. 24.04 ± 3.2 kg/m2, respectively). H-pylori-positive patients had significantly higher HOMA-IR level compared to H-pylori-negative patients (3.54 ± 2.2 vs. 2.46 ± 1.9, respectively) (< 0.05). Fasting serum insulin level was significantly higher in the H-pylori-positive group compared with the H-pylori-negative group (19.41 ± 3.08 vs. 16.57 ± 2.02 μU/ml, respectively) (< 0.05). Our findings suggest recognition of H. pylori infection as a risk factor for insulin resistance.


Insulin resistance Helicobacter pylori HOMA-IR Fasting serum insulin 



The authors thank Dr. Gul Bank, Consultant Diabetes and Endocrinologist, and Dr. Debasish Bannerjee, Consultant Nephrologist, in the St. George’s Hospital, London, for their kind support in the review of this article.


  1. 1.
    Cave DR. Transmission and epidemiology of Helicobacter pylori. Am J Med. 1996;100:12–17. doi: 10.1016/S0002-9343(96)90004-2.CrossRefGoogle Scholar
  2. 2.
    Wyle FA. Helicobacter pylori: current perspectives. J Clin Gastroenterol. 1991;13:114–124. doi: 10.1097/00004836-199112001-00020.CrossRefGoogle Scholar
  3. 3.
    Ernst P. The role of inflammation in the pathogenesis of gastric cancer. Aliment Pharmacol Ther. 1999;13:13–18. doi: 10.1046/j.1365-2036.1999.00003.x.PubMedCrossRefGoogle Scholar
  4. 4.
    Misiewicz JJ. Current insights in the pathogenesis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1995;7:701–703.PubMedGoogle Scholar
  5. 5.
    Pellicano R, Fagoonee S, Rizzetto M, Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Crit Rev Microbiol. 2003;29:351–359.PubMedGoogle Scholar
  6. 6.
    Salteil AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799. doi: 10.1038/414799a.CrossRefGoogle Scholar
  7. 7.
    Moller DE, Flier J. Insulin resistance mechanisms, syndromes and implications. N Engl J Med. 1991;325:938–948.PubMedGoogle Scholar
  8. 8.
    Beckman JA. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570. doi: 10.1001/jama.287.19.2570.PubMedCrossRefGoogle Scholar
  9. 9.
    Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med. 1997;103:152–162. doi: 10.1016/S0002-9343(97)00027-2.PubMedCrossRefGoogle Scholar
  10. 10.
    Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97:996–1001.PubMedGoogle Scholar
  11. 11.
    Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:1894–1900. doi: 10.1097/01.ASN.0000019900.87535.43.PubMedCrossRefGoogle Scholar
  12. 12.
    Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet. 1992;340:930–932. doi: 10.1016/0140-6736(92)92816-X.PubMedCrossRefGoogle Scholar
  13. 13.
    Aydemir S, Bayraktaroglu T, Sert M, et al. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci. 2005;50:2090–2093. doi: 10.1007/s10620-005-3012-z.PubMedCrossRefGoogle Scholar
  14. 14.
    Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495. doi: 10.2337/diacare.27.6.1487.PubMedCrossRefGoogle Scholar
  15. 15.
    Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63. doi: 10.2337/diacare.23.1.57.PubMedCrossRefGoogle Scholar
  16. 16.
    Ferrannini E. Insulin resistance vs insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19:477–490. doi: 10.1210/er.19.4.477.PubMedCrossRefGoogle Scholar
  17. 17.
    Kasuga M. Insulin resistance and pancreatic β cell failure. J Clin Invest. 2006;116:1756–1760. doi: 10.1172/JCI29189.PubMedCrossRefGoogle Scholar
  18. 18.
    Fernández-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19:10–16. doi: 10.1016/j.tem.2007.10.004.PubMedCrossRefGoogle Scholar
  19. 19.
    Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005;307:373–375. doi: 10.1126/science.1104342.PubMedCrossRefGoogle Scholar
  20. 20.
    Mooy JM, de Vries H, Grootenhuis PA, Bouter LM, Heine RJ. Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care. 2000;23:197–201. doi: 10.2337/diacare.23.2.197.PubMedCrossRefGoogle Scholar
  21. 21.
    Foy CG, Bell RA, Farmer DF, Goff DC Jr, Wagenknecht LE. Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2005;28:2501–2507. doi: 10.2337/diacare.28.10.2501.PubMedCrossRefGoogle Scholar
  22. 22.
    Fernández-Real JM, Ferri MJ, Vendrell J, Ricart W. Burden of infection and fat mass in healthy middle-aged men. Obesity (Silver Spring). 2007;15:245–252. doi: 10.1038/oby.2007.541.CrossRefGoogle Scholar
  23. 23.
    Fernández-Real JM, López-Bermejo A, Vendrell J, Ferri MJ, Recasens M, Ricart W. Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care. 2006;29:1058–1064. doi: 10.2337/dc05-2068.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaneko H, Konagaya T, Kusugami K. Helicobacter pylori and gut hormones. J Gastroenterol. 2002;37:77–86. doi: 10.1007/s005350200000.PubMedCrossRefGoogle Scholar
  25. 25.
    Rehfeld JF, Stadil F. The effect of gastrin on basal- and glucose stimulated insulin secretion in man. J Clin Invest. 1973;52:1415–1426. doi: 10.1172/JCI107315.PubMedCrossRefGoogle Scholar
  26. 26.
    Colturi TJ, Unger RH, Feldman M. Role of circulating somatostatin in regulation of gastric acid secretion, gastrin release, and islet cell function. Studies in healthy subjects and duodenal ulcer patients. J Clin Invest. 1984;74:417–423. doi: 10.1172/JCI111437.PubMedCrossRefGoogle Scholar
  27. 27.
    Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation. 2002;105:2646–2652. doi: 10.1161/01.CIR.0000017862.08503.15.PubMedCrossRefGoogle Scholar
  28. 28.
    Wells BJ, Mainous AG, Dickerson LM. Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 2004;164:2156–2161. doi: 10.1001/archinte.164.19.2156.PubMedCrossRefGoogle Scholar
  29. 29.
    Grayston JT, Kronmal RA, Jackson LA, et al; ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637–1645. doi: 10.1056/NEJMoa043526.PubMedCrossRefGoogle Scholar
  30. 30.
    Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science. 1996;274:1185–1188. doi: 10.1126/science.274.5290.1185.PubMedCrossRefGoogle Scholar
  31. 31.
    Salles N, Ménard A, Georges A, et al. Effects of Helicobacter pylori infection on gut appetite peptide (leptin, ghrelin) expression in elderly inpatients. J Gerontol A Biol Sci Med Sci. 2006;61:1144–1150.PubMedGoogle Scholar
  32. 32.
    Lankarani KB, Moghadami M, Masoumpoor M, Geramizadeh B, Omrani GR. Serum leptin level in patients with functional dyspepsia. Dig Liver Dis. 2004;36:717–721. doi: 10.1016/j.dld.2004.07.001.PubMedCrossRefGoogle Scholar
  33. 33.
    Nishi Y, Isomoto H, Uotani S, et al. Enhanced production of leptin in gastric fundic mucosa with Helicobacter pylori infection. World J Gastroenterol. 2005;7:695–699.Google Scholar
  34. 34.
    Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J Natl Med Assoc. 2004;96:1470–1476.PubMedGoogle Scholar
  35. 35.
    Park SH, Jeon WK, Kim SH, et al. Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. J Natl Med Assoc. 2005;97:508–513.PubMedGoogle Scholar
  36. 36.
    Ozdem S, Akcam M, Yilmaz A, Artan R. Insulin resistance in children with Helicobacter pylori infection. J Endocrinol Invest. 2007;30:36–40.Google Scholar
  37. 37.
    Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol. 2007;121:229–238. doi: 10.1016/j.ijcard.2006.12.003.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ahad Eshraghian
    • 1
    • 2
  • Seyed Ali Hashemi
    • 3
  • Alireza Hamidian Jahromi
    • 4
  • Hamed Eshraghian
    • 2
  • Seyed Masoum Masoompour
    • 5
  • Mohamad Ali Davarpanah
    • 5
  • Kavus Eshraghian
    • 1
  • Seyed Alireza Taghavi
    • 2
  1. 1.Internal Medicine DepartmentJahrom University of Medical SciencesJahromIran
  2. 2.Gastroenterology Research CenterShiraz University of Medical SciencesShirazIran
  3. 3.Pathology DepartmentJahrom University of Medical SciencesJahromIran
  4. 4.Renal Transplant UnitSt. George’s HospitalLondonUK
  5. 5.Internal Medicine DepartmentShiraz University of Medical SciencesShirazIran

Personalised recommendations